Loading clinical trials...
Loading clinical trials...
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Qps-Mra, Llc
South Miami, Florida, United States
Qps-Mra,Llc
South Miami, Florida, United States
Altasciences Clinical Kansas, Inc.
Overland Park, Kansas, United States
Start Date
June 25, 2018
Primary Completion Date
May 23, 2019
Completion Date
June 10, 2019
Last Updated
July 1, 2020
98
ACTUAL participants
Placebo
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
PF-06882961
DRUG
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07433062